Isotechnika selected to present at 22nd International Congress of the Transplantation Society

    EDMONTON, Aug. 11 /CNW/ - (ISA:TSX): Isotechnika Inc. today announced two
principal investigators from the Company's recently completed Phase 2b kidney
transplant (PROMISE) trial have been selected to make oral presentations at
the 22nd International Congress of the Transplantation Society Conference in
Sydney, Australia.
    Dr. Herwig Ulf Meier-Kriesche, Professor of Medicine and Clinical
Director of Renal Transplant in the Department of Medicine, University of
Florida will make an oral presentation titled "Using Voclosporin
Pharmacokinetics (Concentration) and Pharmacodynamics (Calcineurin Activity)
to Predict Optimum Immunosuppression in a Phase 2b Renal Transplantation
Trial" during the late-breaking session on August 12th. Another oral
presentation titled "Voclosporin: The Phase 2 'PROMISE' de novo Renal
Transplant Trial Demonstrates Efficacy and an Improved Safety Profile Across a
Wide Therapeutic Range" will be made by Dr. Stephan Busque, Associate
Professor of Surgery and Director, Adult Kidney & Pancreas Transplant Program
at the Stanford University School of Medicine during the late-breaking session
on August 14th.
    Interested parties will be able to access the presentations by visiting
the "Presentations" folder in the "For Investors" section of the Company's
corporate website at

    About Isotechnika
    Edmonton-based Isotechnika Inc. is an international biopharmaceutical 
company focused on the discovery and development of novel immunosuppressive
therapeutics that are designed to offer advantages over other currently
available treatments. There is a significant unmet medical need in the
treatment of both solid organ transplantation and autoimmune disease. It is
estimated that the market potential will exceed $4 billion annually in sales
for calcineurin inhibitors such as voclosporin by 2010.
    Voclosporin is a next generation calcineurin inhibitor, which recently
completed a Phase 2b North American trial for the prevention of kidney
rejection following transplantation. An extension to the Phase 2b trial and a
combined Phase 3 European/Canadian trial for the treatment of moderate to
severe psoriasis are ongoing. Our partner, Lux Biosciences, is currently
conducting three separate Phase 2/3 pivotal trials investigating voclosporin
(referred to as LUVENIQ(TM) by Lux) for the treatment of uveitis. Voclosporin
has also entered First-in-Man trials as the drug utilized in the CINATRA(TM)
Drug Coated Coronary Stent system developed by the Company's partner, Atrium
Medical Corporation.
    Isotechnika Inc. is a publicly traded company on the Toronto Stock
Exchange under the symbol "ISA". More information on Isotechnika can be found
at or

    Forward-Looking Statements
    This press release may contain forward-looking statements. Forward
looking statements, including the Company's belief as to the potential of its
products, the Company's expectations regarding the issuance of additional
patents and the Company's ability to protect its intellectual property,
involve known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the forward
looking statements. Such risks and uncertainties include, among others, the
availability of funds and resources to pursue research and development
projects, the ability to economically manufacture its products, the potential
of its products, the success and timely completion of clinical studies and
trials, the Company's ability to successfully commercialize its products, the
ability of the Company to defend its patents from infringement by third
parties, and the risk that the Company's patents may be subsequently shown to
be invalid or infringe the patents of others. Investors should consult the
Company's quarterly and annual filings with the Canadian commissions for
additional information on risks and uncertainties relating to the forward-
looking statements. Investors are cautioned against placing undue reliance on
forward-looking statements.

For further information:

For further information: Stephanie Gillis-Paulgaard, Director, Corporate
Communications, Isotechnika Inc., Phone: (780) 909-4661, Fax: (780) 484-4105,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890